REBUILD-1: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Study Details
Study Description
Brief Summary
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
The study has two parts which enroll separately from each other such that participants may choose to participate in either but not both: the main study and a study addendum.
-
The main study includes a 3-month, randomized, double-blind treatment period in which participants receive either galcanezumab or placebo, followed by a 9-month open-label extension in which all participants receive galcanezumab.
-
The study addendum is a stand-alone study of galcanezumab pharmacokinetics and safety in a group of participants separate from those in the main study. The study addendum includes a 5-month evaluation period after a single injection of galcanezumab, followed by a 9-month open-label extension.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Galcanezumab Galcanezumab administered by SQ injection. Participants may be eligible for optional open-label extension at the end of the double-blind period. |
Drug: Galcanezumab
Administered SQ
Other Names:
|
Placebo Comparator: Placebo Placebo administered by SQ injection. Participants may be eligible for optional open-label extension at the end of the double-blind period. |
Drug: Placebo
Administered SQ
|
Outcome Measures
Primary Outcome Measures
- Change from Baseline in the Number of Monthly Migraine Headache Days [Baseline, 3 Months]
Change from baseline in the number of monthly migraine headache days
Secondary Outcome Measures
- Percentage of Participants with Reduction from Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days [3 Months]
Percentage of participants with reduction from baseline ≥50%, ≥75% and 100% in monthly migraine headache days
- Change from Baseline in the Number of Monthly Migraine Headache Days with Nausea and/or Vomiting [Baseline, 3 Months]
Change from baseline in the number of monthly migraine headache days with nausea and/or vomiting
- Change from Baseline in the Number of Monthly Migraine Headache Days with Photophobia and Phonophobia [Baseline, 3 Months]
Change from baseline in the number of monthly migraine headache days with photophobia and phonophobia
- Change from Baseline in the Number of Monthly Migraine Headaches with Prodromal Symptoms [Baseline, 3 Months]
Change from baseline in the number of monthly migraine headaches with prodromal symptoms
- Change from Baseline in the Number of Migraine Headache Days on which Acute Headache Medication is Taken [Baseline, 3 Months]
Change from baseline in the number of migraine headache days on which acute headache medication is taken
- Patient Global Impression-Improvement (PGI-I) Rating [Month 1 to Month 3]
PGI-I rating
- Change from Baseline in the Severity of Remaining Migraine Headaches per Month [Baseline, 3 Months]
Change from baseline in the severity of remaining migraine headaches per month
- Change from Baseline in the Number of Monthly Headache Days [Baseline, 3 Months]
Change from baseline in the number of monthly headache days
- Change from Baseline on the Pediatric Quality of Life Inventory (PedsQL) Total Score [Baseline, 3 Months]
Change from Baseline on the PedsQL total score
- Change from Baseline on the Pediatric Migraine Disability Assessment Test (PedMIDAS) Total Score [Baseline, 3 Months]
Change from baseline on the PedMIDAS total score
- Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Score [Baseline through 3 Months]
Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the C-SSRS Score
- Pharmacokinetics (PK): Serum Concentration of Galcanezumab [Baseline through 3 Months]
PK: Serum concentration of galcanezumab
- Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP) [Baseline through 3 Months]
Plasma concentration of CGRP
- Percentage of Participants Developing Anti-Drug Antibodies [Baseline through 3 Months]
Percentage of participants developing anti-drug antibodies
- Percentage of Participants who Initiate Migraine Prevention Medication in the Post-Treatment Follow-Up Phase [16 Months]
Percentage of participants who initiate migraine prevention medication in the post-treatment follow-up phase
Eligibility Criteria
Criteria
Inclusion Criteria:
- Have a diagnosis of migraine with or without aura as defined by the IHS ICHD-3 guidelines (1.1 or 1.2 according to ICHD-3 [2018]), with a history of migraine headaches of at least 6 months prior to screening.
Exclusion Criteria:
-
Participants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). Prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline.
-
Known hypersensitivity to monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients.
-
Current use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody.
-
History of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine).
-
History of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury.
-
Participants with a known history of intracranial tumors or developmental malformations including Chiari malformations.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Rehabilitation & Neurological Services | Huntsville | Alabama | United States | 35805-4046 |
2 | 21st Century Neurology, a division of Xenoscience | Phoenix | Arizona | United States | 85004 |
3 | Barrow Neurological Institute at Phoenix Children's Hospital | Phoenix | Arizona | United States | 85016 |
4 | Center for Neurosciences | Tucson | Arizona | United States | 85718 |
5 | MemorialCare Health System - Long Beach Medical Center | Long Beach | California | United States | 90806 |
6 | Orange County Research Institute - Ontario | Ontario | California | United States | 91762 |
7 | Medical Center For Clinical Research | San Diego | California | United States | 92120 |
8 | Children's Hospital Colorado | Aurora | Colorado | United States | 80045 |
9 | Clinical Neuroscience Solutions Inc | Jacksonville | Florida | United States | 32256 |
10 | Alphab Global Research | Jupiter | Florida | United States | 33458 |
11 | Jackson Memorial Hospital | Miami | Florida | United States | 33136 |
12 | Ezy Medical Research | Miami | Florida | United States | 33175 |
13 | Sensible Healthcare, LLC | Ocoee | Florida | United States | 34761 |
14 | Psychiatric Inst of Florida-Clinical Neuroscience Solutions | Orlando | Florida | United States | 32801 |
15 | Clinical Research Center of Florida | Pompano Beach | Florida | United States | 33060 |
16 | University of South Florida | Tampa | Florida | United States | 33612-4799 |
17 | ForCare Clinical Research | Tampa | Florida | United States | 33613 |
18 | Northwest Clinical Trials | Boise | Idaho | United States | 83704 |
19 | Advanced Clinical Research LLC | Meridian | Idaho | United States | 83642 |
20 | Alexian Brothers Medical Center | Hoffman Estates | Illinois | United States | 60169 |
21 | University of Kentucky College of Medicine | Lexington | Kentucky | United States | 40504 |
22 | Pharmasite Research, Inc. | Baltimore | Maryland | United States | 21208 |
23 | Boston Clinical Trials | Boston | Massachusetts | United States | 02131 |
24 | New England Neurological Associates, PC | Lawrence | Massachusetts | United States | 01843 |
25 | MedVadis Research Corporation | Waltham | Massachusetts | United States | 02451 |
26 | Minneapolis Clinic of Neurology | Burnsville | Minnesota | United States | 55337 |
27 | Children Mercy Pediatric Clinical Research Unit | Kansas City | Missouri | United States | 64108 |
28 | Dent Neurologic Institute | Amherst | New York | United States | 14226-0000 |
29 | Northwell Health | Great Neck | New York | United States | 11021 |
30 | Northwell Health- Division of Pediatric Neurology | Lake Success | New York | United States | 11042 |
31 | Cincinnati Childrens Hospital Medical Center | Cincinnati | Ohio | United States | 45229 |
32 | UPMC Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | United States | 15224 |
33 | Preferred Primary Care Physicians | Pittsburgh | Pennsylvania | United States | 15236 |
34 | Velocity Clinical Research | East Greenwich | Rhode Island | United States | 02818 |
35 | University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | United States | 75390-9063 |
36 | Houston Neurology Clinical & Diagnostic Consultants | Houston | Texas | United States | 77054 |
37 | Northwest Clinical Research Center | Bellevue | Washington | United States | 98007-4209 |
38 | Seattle Children's Research Institute | Seattle | Washington | United States | 98105 |
39 | Sanos Clinic Gandrup | Gandrup | North Jutland | Denmark | 9362 |
40 | Herlev Universitets Hospital | Herlev | Denmark | 2730 | |
41 | Praxis Dr. med. Astrid Gendolla Praxis für Neurologie, Psychosomatik,Nervenheilkunde, Psychotherapieund Spezielle Schmerztherapie | Essen | Nordrhein-Westfalen | Germany | 45133 |
42 | G.B. Pant Institute of Postgraduate Medical Education & Research | New Delhi | Delhi | India | 110002 |
43 | All India Institute of Medical Sciences | New Delhi | Delhi | India | 110029 |
44 | Sir Ganga Ram Hospital | New Delhi | Delhi | India | 110060 |
45 | Panchshil hospital | Ahmedabad | Gujarat | India | 380005 |
46 | Mangala Hospital & Mangala Kidney Foundation | Mangalore | Karnataka | India | 575003 |
47 | Getwell Hospital and Research Institute | Nagpur | Maharashtra | India | 440012 |
48 | All India Institute of Medical Sciences - Nagpur | Nagpur | Maharashtra | India | 441108 |
49 | Apollo Gleneagles Hospitals Kolkata | Kolkata | West Bengal | India | 700054 |
50 | Central India Cardiology and Research Institute | Nagpur | India | 440015 | |
51 | UOSD di Neuropsichiatria Infantile | Napoli | Naples | Italy | 80131 |
52 | Istituto Neurologico Carlo Besta | Milano | Italy | 20133 | |
53 | Ospedale Bambino Gesu | Roma | Italy | 00165 | |
54 | Università degli Studi di Roma La Sapienza - Policlinico Umberto I | Roma | Italy | 00185 | |
55 | Konan Hospital | Kobe | Hyogo | Japan | 658-0064 |
56 | Yamaguchi Clinic | Nishinomiya | Hyogo | Japan | 663-8204 |
57 | Sendai Headache and Neurology Clinic | Sendai | Miyagi | Japan | 982-0014 |
58 | Tokyo Medical University Hospital | Shinjuku-ku | Tokyo | Japan | 160-0023 |
59 | Umenotsuji Clinic | Kochi | Japan | 780-8011 | |
60 | Tatsuoka Neurology Clinic | Kyoto | Japan | 600-8811 | |
61 | Tominaga Hospital | Osaka | Japan | 556-0017 | |
62 | Tokyo Headache Clinic | Tokyo | Japan | 151-0051 | |
63 | Hospital Infantil de Mexico Federico Gomez | Ciudad de Mexico | Federal District | Mexico | 06720 |
64 | Hospital Civil Fray Antonio Alcalde | Guadalajara | Jalisco | Mexico | 44280 |
65 | PanAmerican Clinical Research S.A.de C.V. Guadalajara | Guadalajara | JA | Mexico | 44670 |
66 | Clinica De Enfermedades Cronicas y Procedimientos Especiales | Morelia | Michoacan | Mexico | 58249 |
67 | Centro de Investigacion Medica Aguascalientes | Aguascalientes | Mexico | 20116 | |
68 | Unidad de Investigación en Salud | Chihuahua | Mexico | 31203 | |
69 | Isala, locatie Zwolle | Zwolle | Overijssel | Netherlands | 8025 AB |
70 | Dr. Samuel Sanchez PSC | Caguas | Puerto Rico | 00727 | |
71 | Ponce School of Medicine CAIMED Center | Ponce | Puerto Rico | 00716 | |
72 | Barbara Diaz Hernandez | San Juan | Puerto Rico | 00927 | |
73 | Hospital de la Santa Creu i Sant Pau | Barcelona | Spain | 08025 | |
74 | Hospital Universitari Vall d'Hebron | Barcelona | Spain | 08035 | |
75 | Hospital Universitario Virgen Del Rocio | Sevilla | Spain | 41013 | |
76 | Hospital Clínico Universitario de Valencia | Valencia | Spain | 46010 | |
77 | Hospital Clinico Universitario de Valladolid | Valladolid | Spain | 47010 |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 16352
- I5Q-MC-CGAS
- 2017-004351-23